148 related articles for article (PubMed ID: 4724016)
1. Differential effects of benzodioxane, chroman and dihydrobenzofuran analogs of clofibrate in a Triton hyperlipemic rat model.
Newman HA; Heilman WP; Witiak DT
Lipids; 1973 Jul; 8(7):378-84. PubMed ID: 4724016
[No Abstract] [Full Text] [Related]
2. Differential effects of benzodioxane, chroman, and dihydrobenzofuran analogs of clofibrate on various parameters of hepatic drug metabolism.
Lewis NJ; Feller DR; Poochikian GK; Witiak DT
J Med Chem; 1974 Jan; 17(1):41-5. PubMed ID: 4808468
[No Abstract] [Full Text] [Related]
3. Triton-induced hyperlipidemia in rats as an animal model for screening hypolipidemic drugs.
Schurr PE; Schultz JR; Parkinson TM
Lipids; 1972 Jan; 7(1):68-74. PubMed ID: 5013174
[No Abstract] [Full Text] [Related]
4. Antilipidemic activity of 4-oxo-functionalized ethyl 6-chlorochroman-2-carboxylate analogs and a related tricyclic lactone in three rat models.
Cavestri RC; Minatelli JA; Baldwin JR; Loh W; Feller DR; Newman HA; Sober CL; Witiak DT
Lipids; 1981 Jan; 16(1):30-6. PubMed ID: 7219078
[TBL] [Abstract][Full Text] [Related]
5. Hypolipidemic effects of clofibrate and selected chroman analogs in fasted rats: I. Chow-fed animals.
O'Brien M; Patel ST; Mukhopadhyay A; Newman HA; Feller DR; Kokrady SS; Witiak DT; Lanese RR; Rice JC
Lipids; 1981 Dec; 16(12):903-11. PubMed ID: 7329211
[TBL] [Abstract][Full Text] [Related]
6. Antihyperlipidemic effect of flavonoids from Pterocarpus marsupium.
Jahromi MA; Ray AB
J Nat Prod; 1993 Jul; 56(7):989-94. PubMed ID: 8377021
[TBL] [Abstract][Full Text] [Related]
7. Comparative antilipidemic effects of various ethyl 5-substituted benzofuran-, 2,3-dihydrobenzofuran-, and 3(2H)-benzofuranone-2-carboxylate analogs of clofibrate in a triton hyperlipidemic rat model.
Witiak DT; Newman HA; Poochikian GK; Loh W; Sankarappa SK
Lipids; 1976 May; 11(5):384-91. PubMed ID: 1271976
[TBL] [Abstract][Full Text] [Related]
8. Synthesis of ethyl 6-substituted-chroman- and -chromone-2-carboxylates. A comparative structure-activity study employing the 6-phenyl and phenoxy analogs in the triton hyperlipidemic rat model.
Witiak DT; Heilman WP; Sankarappa SK; Cavestri RC; Newman HA
J Med Chem; 1975 Sep; 18(9):935-42. PubMed ID: 1159716
[TBL] [Abstract][Full Text] [Related]
9. Effect of KC-9432, a new hypolipidemic compound, on high density lipoprotein cholesterol in rats.
Seri K; Sato R; Hamazaki Y; Yamamoto T; Ishiyama N
Atherosclerosis; 1980 Sep; 37(1):97-102. PubMed ID: 6893550
[TBL] [Abstract][Full Text] [Related]
10. [Effect of ethofibrate [2-(nicotinoyloxy)ethyl-p-chlorophenoxyisobutyrate] on lipid metabolism. I. Effect on blood lipids in normal and hyperlipemic rats].
Maroto ML; Priego JG; Piña M; Catalán RE
Arch Farmacol Toxicol; 1978 Apr; 4(1):25-7. PubMed ID: 697396
[No Abstract] [Full Text] [Related]
11. Diethyl (4baalpha,4calpha,9aalpha,9balpha)-3,6-dichlorocyclobuta[1,2-b:3,4-b']bisbenzofuran-9a,9b(4bH,4cH)-dicarboxylate: the cis,syn photodimer of ethyl 5-chlorobenzofuran-2-carboxylate, an analogue related to the antilipidemic drug clofibrate.
Witiak DT; Newman HA; Poochikian GK; Fogt SW; Baldwin JR; Sober CL; Feller DR
J Med Chem; 1978 Aug; 21(8):833-7. PubMed ID: 99517
[TBL] [Abstract][Full Text] [Related]
12. Effect of clofibrate on plasma lipids of rat and rabbit.
Byers SO; Friedman M
Atherosclerosis; 1970; 11(3):373-82. PubMed ID: 5433083
[No Abstract] [Full Text] [Related]
13. [The treatment of essential hyperlipidemia with clofibrate].
Reuter W; Seifert A
Z Gesamte Inn Med; 1969 Jan; 24(1):Suppl:184-7. PubMed ID: 4918619
[No Abstract] [Full Text] [Related]
14. Isonicotinates, nicotinates and clofibrates of N-methyl-N-(2-hydroxyethyl or 3-hydroxypropyl)--1,3,3-trimethylbicyclo [2.2.1]heptan-2-endo-amine with hypocholesterolemic and hypolipidemic activity.
Bondavalli F; Bruno O; Schenone P; Vacca C; De Carlo R; Marmo E
Farmaco Sci; 1987 Apr; 42(4):251-7. PubMed ID: 3595837
[TBL] [Abstract][Full Text] [Related]
15. Hypolipidemic effects of clofibrate and selected chroman analogs in fasted rats: II. High sucrose-fed animals.
Mukhopadhyay A; Patel ST; O'Brien M; Kokrady SS; Newman HA; Witiak DT; Lanese RR; Rice JC; Feller DR
Lipids; 1983 Jan; 18(1):59-67. PubMed ID: 6835036
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological studies on experimental nephritic rats. (4) Improvement of hyperlipemic models in rats utilizing anti-rat kidney rabbit serum and effects of anti-hyperlipemic agents on serum lipid levels.
Suzuki Y; Honda Y; Ito M
Jpn J Pharmacol; 1978 Oct; 28(5):729-38. PubMed ID: 723001
[TBL] [Abstract][Full Text] [Related]
17. Potential hypolipidemic agents. 7. Synthesis and lipid-lowering properties of 2-(dibenzofuranyloxy)-2-methylpropionates and related compounds.
Bondesson G; Hedbom C; Högberg T; Magnusson O; Stjernström NE; Carlson LA
J Med Chem; 1974 Jan; 17(1):108-12. PubMed ID: 4808456
[No Abstract] [Full Text] [Related]
18. Hypolipidaemic activity of orally administered diphenyl diselenide in Triton WR-1339-induced hyperlipidaemia in mice.
da Rocha JT; Sperança A; Nogueira CW; Zeni G
J Pharm Pharmacol; 2009 Dec; 61(12):1673-9. PubMed ID: 19958591
[TBL] [Abstract][Full Text] [Related]
19. The spontaneously hyperlipidemic old rat as a model for evaluation of hypolipoproteinemic drugs. Effects of nicotinic acid, clofibrate and ethyl 2-(4-dibenzofuranyloxy)-2-methylpropionate on plasma lipoproteins.
Gustafsson K; Kiessling H
Z Versuchstierkd; 1982; 24(5-6):262-70. PubMed ID: 7170838
[No Abstract] [Full Text] [Related]
20. 5-(Tetradecyloxy)-2-furancarboxylic acid and related hypolipidemic fatty acid-like alkyloxyarylcarboxylic acids.
Parker RA; Kariya T; Grisar JM; Petrow V
J Med Chem; 1977 Jun; 20(6):781-91. PubMed ID: 406395
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
